Stock VO2 VO2 CAP HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Vo2 Cap Holding AB

Equities

VO2

SE0016802797

Delayed Nasdaq Stockholm
Other stock markets
 11:34:06 14/05/2024 BST 		5-day change 1st Jan Change
2.88 SEK -0.69% Intraday chart for Vo2 Cap Holding AB -1.02% -0.68%
2023 Ratsave AB acquired additional minority stake in Vo2 Cap Holding AB (OM:VO2) from Oskar Sardi. CI
2023 Vo2 Cap Holding AB (OM:VO2) entered into an agreement to acquire Madington Ab for SEK 65 million. CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.7 for the 2024 fiscal year.
  • The company appears to be poorly valued given its net asset value.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The firm trades with high earnings multiples: 36.25 times its 2024 earnings per share.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
VO2 CAP HOLDING AB Stock Vo2 Cap Holding AB
-0.68% 14.3M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+5.89% 32.95B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+18.09% 7.82B
C-
SECTRA AB Stock Sectra AB
+32.70% 4.17B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-28.10% 2.72B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-18.15% 1.41B
B
LUNIT INC. Stock Lunit Inc.
-33.33% 1.15B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+9.61% 980M
C
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-37.56% 873M -
VERADIGM INC. Stock Veradigm Inc.
-26.41% 831M -
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VO2 Stock
  4. Ratings Vo2 Cap Holding AB